Virtual screening of novel pyridine derivatives as effective inhibitors of DNA gyrase (GyrA) of salmonella typhi

In a bid to discovering novel antibiotics to combat growing trend of multi-drug resistance strains of Salmonella typhi, 48 new pyridine derivatives with significant inhibitory activities against the aforementioned bacterium were subjected to molecular docking against DNA gyrase protease of...

Full description

Bibliographic Details
Main Authors: John Ameji Philip, Adamu Uzairu, Gideon Adamu Shallangwa, Sani Uba
Format: Article
Language:English
Published: Growing Science 2023-01-01
Series:Current Chemistry Letters
Online Access:http://www.growingscience.com/ccl/Vol12/ccl_2022_46.pdf
_version_ 1811339269279580160
author John Ameji Philip
Adamu Uzairu
Gideon Adamu Shallangwa
Sani Uba
author_facet John Ameji Philip
Adamu Uzairu
Gideon Adamu Shallangwa
Sani Uba
author_sort John Ameji Philip
collection DOAJ
description In a bid to discovering novel antibiotics to combat growing trend of multi-drug resistance strains of Salmonella typhi, 48 new pyridine derivatives with significant inhibitory activities against the aforementioned bacterium were subjected to molecular docking against DNA gyrase protease of the bacterium, drug likeness evaluation and pharmacokinetics profiling. All the 48 leads displayed better binding affinity values when compared with Amoxicillin, Ciprofloxacin, Ceftriaxone, Ampicillin, and chloramphenicol, the standard antibiotics used herein for quality assurance. Furthermore, the majority of the compounds were, however, screened out due to their poor pharmacokinetics profiles and drug-likeness. Only five compounds emerged as the most promising leads and they include C4 with binding affinity of -8.0 kcal/mol, C8 (-8.6 kcal/mol), C9 (-8.1 kcal/mol), C26 (-8.3 kcal/mol), and C27 (-8.0 kcal/mol). These compounds not only displayed better binding affinity when compared with the reference antibiotics but also exhibit different modes of interactions with the target protease of the bacterium making them more potent and drug like. Toxicity evaluation of the leads also revealed that the compounds are neither tumorigenic nor mutagenic. In view of the excellent binding affinity, high pharmacokinetics profile and positive drug-likeness of the novel ligands, we recommend these promising compounds for in vitro and in vivo studies in order to discover novel antibiotics that could curb the dangerous trend of multiple drug resistance by Salmonella typhi.
first_indexed 2024-04-13T18:23:46Z
format Article
id doaj.art-c1cb53f2036943a2b0d45b610d1c57d6
institution Directory Open Access Journal
issn 1927-7296
1927-730X
language English
last_indexed 2024-04-13T18:23:46Z
publishDate 2023-01-01
publisher Growing Science
record_format Article
series Current Chemistry Letters
spelling doaj.art-c1cb53f2036943a2b0d45b610d1c57d62022-12-22T02:35:19ZengGrowing ScienceCurrent Chemistry Letters1927-72961927-730X2023-01-0112111610.5267/j.ccl.2022.10.002Virtual screening of novel pyridine derivatives as effective inhibitors of DNA gyrase (GyrA) of salmonella typhiJohn Ameji PhilipAdamu UzairuGideon Adamu ShallangwaSani Uba In a bid to discovering novel antibiotics to combat growing trend of multi-drug resistance strains of Salmonella typhi, 48 new pyridine derivatives with significant inhibitory activities against the aforementioned bacterium were subjected to molecular docking against DNA gyrase protease of the bacterium, drug likeness evaluation and pharmacokinetics profiling. All the 48 leads displayed better binding affinity values when compared with Amoxicillin, Ciprofloxacin, Ceftriaxone, Ampicillin, and chloramphenicol, the standard antibiotics used herein for quality assurance. Furthermore, the majority of the compounds were, however, screened out due to their poor pharmacokinetics profiles and drug-likeness. Only five compounds emerged as the most promising leads and they include C4 with binding affinity of -8.0 kcal/mol, C8 (-8.6 kcal/mol), C9 (-8.1 kcal/mol), C26 (-8.3 kcal/mol), and C27 (-8.0 kcal/mol). These compounds not only displayed better binding affinity when compared with the reference antibiotics but also exhibit different modes of interactions with the target protease of the bacterium making them more potent and drug like. Toxicity evaluation of the leads also revealed that the compounds are neither tumorigenic nor mutagenic. In view of the excellent binding affinity, high pharmacokinetics profile and positive drug-likeness of the novel ligands, we recommend these promising compounds for in vitro and in vivo studies in order to discover novel antibiotics that could curb the dangerous trend of multiple drug resistance by Salmonella typhi.http://www.growingscience.com/ccl/Vol12/ccl_2022_46.pdf
spellingShingle John Ameji Philip
Adamu Uzairu
Gideon Adamu Shallangwa
Sani Uba
Virtual screening of novel pyridine derivatives as effective inhibitors of DNA gyrase (GyrA) of salmonella typhi
Current Chemistry Letters
title Virtual screening of novel pyridine derivatives as effective inhibitors of DNA gyrase (GyrA) of salmonella typhi
title_full Virtual screening of novel pyridine derivatives as effective inhibitors of DNA gyrase (GyrA) of salmonella typhi
title_fullStr Virtual screening of novel pyridine derivatives as effective inhibitors of DNA gyrase (GyrA) of salmonella typhi
title_full_unstemmed Virtual screening of novel pyridine derivatives as effective inhibitors of DNA gyrase (GyrA) of salmonella typhi
title_short Virtual screening of novel pyridine derivatives as effective inhibitors of DNA gyrase (GyrA) of salmonella typhi
title_sort virtual screening of novel pyridine derivatives as effective inhibitors of dna gyrase gyra of salmonella typhi
url http://www.growingscience.com/ccl/Vol12/ccl_2022_46.pdf
work_keys_str_mv AT johnamejiphilip virtualscreeningofnovelpyridinederivativesaseffectiveinhibitorsofdnagyrasegyraofsalmonellatyphi
AT adamuuzairu virtualscreeningofnovelpyridinederivativesaseffectiveinhibitorsofdnagyrasegyraofsalmonellatyphi
AT gideonadamushallangwa virtualscreeningofnovelpyridinederivativesaseffectiveinhibitorsofdnagyrasegyraofsalmonellatyphi
AT saniuba virtualscreeningofnovelpyridinederivativesaseffectiveinhibitorsofdnagyrasegyraofsalmonellatyphi